Lario Therapeutics awarded $2.4m by The Michael J. Fox Foundation and Wellcome to expand neuronal calcium channel platform across CNS disorders
- New prestigious grants support Lario’s unique portfolio of calcium channel programmes
- Indication expansion into Parkinson’s disease, and PTSD (post-traumatic stress disorders)
- Builds on prior support from The Michael J. Fox Foundation and further validates Lario’s precision neuroscience platform
Edinburgh, UK – 19 February 2026 – Lario Therapeutics (“Lario” or the “Company”), a biopharmaceutical company developing first-in-class precision medicines for epileptic and neurological disorders, today announced it has received a total of $2.4 million in grant funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Wellcome to support the continued expansion of its neuronal calcium channel drug discovery platform.
